Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
10.1002/cpdd.427
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
WILEY
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/218636 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
id |
sg-nus-scholar.10635-218636 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-2186362023-10-31T20:32:36Z Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC Tan, Eng-Huat Lim, Wan-Teck Ahn, Myung-Ju Ng, Quan-Sing Ahn, Jin Seok Tan, Daniel Shao-Weng Sun, Jong-Mu Han, May Payumo, Francis C Mckee, Krista Yin, Wei Credi, Marc Agarwal, Shefali Jac, Jaroslaw Park, Keunchil DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA 10.1002/cpdd.427 CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT 7 5 532-542 2022-04-07T09:30:27Z 2022-04-07T09:30:27Z 2018-06-01 2022-04-07T02:43:18Z Article Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil (2018-06-01). Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT 7 (5) : 532-542. ScholarBank@NUS Repository. https://doi.org/10.1002/cpdd.427 21607648 https://scholarbank.nus.edu.sg/handle/10635/218636 en WILEY Elements |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
language |
English |
topic |
Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA |
spellingShingle |
Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA Tan, Eng-Huat Lim, Wan-Teck Ahn, Myung-Ju Ng, Quan-Sing Ahn, Jin Seok Tan, Daniel Shao-Weng Sun, Jong-Mu Han, May Payumo, Francis C Mckee, Krista Yin, Wei Credi, Marc Agarwal, Shefali Jac, Jaroslaw Park, Keunchil Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
description |
10.1002/cpdd.427 |
author2 |
DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) |
author_facet |
DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) Tan, Eng-Huat Lim, Wan-Teck Ahn, Myung-Ju Ng, Quan-Sing Ahn, Jin Seok Tan, Daniel Shao-Weng Sun, Jong-Mu Han, May Payumo, Francis C Mckee, Krista Yin, Wei Credi, Marc Agarwal, Shefali Jac, Jaroslaw Park, Keunchil |
format |
Article |
author |
Tan, Eng-Huat Lim, Wan-Teck Ahn, Myung-Ju Ng, Quan-Sing Ahn, Jin Seok Tan, Daniel Shao-Weng Sun, Jong-Mu Han, May Payumo, Francis C Mckee, Krista Yin, Wei Credi, Marc Agarwal, Shefali Jac, Jaroslaw Park, Keunchil |
author_sort |
Tan, Eng-Huat |
title |
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
title_short |
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
title_full |
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
title_fullStr |
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
title_full_unstemmed |
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC |
title_sort |
phase 1b trial of ficlatuzumab, a humanized hepatocyte growth factor inhibitory monoclonal antibody, in combination with gefitinib in asian patients with nsclc |
publisher |
WILEY |
publishDate |
2022 |
url |
https://scholarbank.nus.edu.sg/handle/10635/218636 |
_version_ |
1781793042864275456 |